You are correct MT2, with the usual major hurdles to investing in biotechs already well resolved. Firstly the usual lenghty time delay from lab to testing is essentially over as we await current phase II completion. Secondly, normal cash burn during testing is not an issue with the USA armed forces covering the traumatic brain injury trials. Motiva has huge potential and the anti cancer studies are yet to proceed. All in all, a better than usual long term prospect.
62c npv; $2b potential sales; us army backing, page-2
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
0.000(0.00%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $21.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.51 | 19 | 3 |
View Market Depth
| Last trade - 09.44am 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable